• The Journal of the Korean Society for Microbiology
• /
• v.16 no.1
• /
• pp.57-64
• /
• 1981

The clinical need for agents to modify immune response in the treatment of viral infection has lead to an increased interest in cellular and biochemical mechanisms regulating the immune response and to the development of a variety of biological and chemical substance with immunomodulatory activity. Inosiplex has shown antiviral activity in tissue culture, animal models and huamn studies through augmentation of immune response. However, the effect of inosiplex on immune response in animal has not been extensively analyzed, and the effect of inosiplex on immune response has been paradoxical depending on the time of administration of inosiplex in relation to that of antigen. Therefore, this study was undertaken to assess the effect of inosiplex on the immune response to sheep red blood cells(SRBC) in normal and viral infected mice. Inosiplex increased cellular immune response and plaque forming lymphocyte response to SRBC, decreased the recovery of S. typhimurium from infected mice spleen, and restored the depressed cellular immune response by measle and newcastle disease virus infections. All of the above results were observed only when inosiplex was given after immunization but did not when given before immunization. These results indicate that inosiplex stimulate the efferent are of immune response and may even block the afferent are, and suggest that inosiplex is a very promising drug in therapy of many viral infections.

• The Journal of the Korean Society for Microbiology
• /
• v.22 no.3
• /
• pp.323-328
• /
• 1987

This study was attempted to investigate the effect of inosiplex on the cell-mediated immunity in the patients with lepromatous leprosy. Fourteen patients received inosiplex (6gm/day) for 1 month. About 20% of the patients (3 of 14) showed conversion of the lepromin reaction and bacteriological index was significantly decreased in 3 of 7 patients. However, inosiplex administration had no effect on the lymphocyte blastogenesis to M. leprae. The clinical evolution showed a favorable activity of the drug on cutaneous lesions in some patients. The tolerance of the drug was excellent. No side effects were observed. These results suggest that inosiplex may have a moderate immunopotential value in lepromatous leprosy.

• The Journal of the Korean Society for Microbiology
• /
• v.21 no.2
• /
• pp.251-259
• /
• 1986

This study was performed to assess the effect of inosiplex(ISP) on the resistance of mice Candida albicans infection, the migration of chicken leukocytes, the production of leukocyte migration inhibitory factor(LIF), and the cell-mediated immunity(CMI) to lepomin in multibacillary lepromatous leprosy patients. The treatment with ISP before or on the time of infection with C. albicans had no or deliterious effect, and treatment with ISP after infection had no effect on the recovery of C. albicans from the kidneys of mice. The migratory ability of chicken leukocytes and the production of LIF from splenocytes of mice were not affected by ISP treatment. However, ISP decreased the migration of chicken leukocytes in vitro, and this decrease was dose-dependent. The therapy of lepromatous leprosy patients with ISP for 10 or 30 days clearly showed the increase of the significant positive rate of Mitsuda skin test to lepromin. The immune recovery as a result of the therapy was found to be the best in the group of patients treated for 30 days. This results suggest that (1) the effect of ISP in renal candidiasis can vary depending on the time of treatment relative to infection, (2) ISP can primarily change the migratory ability of chicken leukocytes but does not affect the production of LIF in mice, and (3) the classical therapy combined with ISP can reinforce or restore the defences of lepromatous leprosy patients against Mycobacterium leprae.